Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Published:2010-07 Issue:7 Volume:11 Page:619-626
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Herbst Roy S,Sun Yan,Eberhardt Wilfried EE,Germonpré Paul,Saijo Nagahiro,Zhou Caicun,Wang Jie,Li Longyun,Kabbinavar Fairooz,Ichinose Yukito,Qin Shukui,Zhang Li,Biesma Bonne,Heymach John V,Langmuir Peter,Kennedy Sarah J,Tada Hiroomi,Johnson Bruce E

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

4. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 370 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer;AAPS Open;2024-06-17

2. Assurance methods for designing a clinical trial with a delayed treatment effect;Statistics in Medicine;2024-06-16

3. Beyond Chemoimmunotherapy in Advanced Non–Small Cell Lung Cancer: New Frontiers, New Challenges;American Society of Clinical Oncology Educational Book;2024-06

4. Nintedanib in Combination With Chemotherapy in the Treatment of Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Cureus;2024-02-07

5. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer;Clinical and Translational Oncology;2023-12-25